Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 6/20 | 1.00 |
| ▸ | POLB | P06746 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.62 |
| ▸ | GFER | P55789 | 1/20 | 0.62 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.62 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.61 |
| ▸ | GSK3A | P49840 | 2/20 | 0.61 |
| ▸ | GSK3B | P49841 | 2/20 | 0.61 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.60 |
| ▸ | BRAF | P15056 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.56 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.56 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31434334 | 1.00 | PIM1 (1.00) | PIM1POLBMEN1KMT2AGFER | |
| SCHEMBL700411 | 1.00 | PIM1 (1.00) | PIM1POLBMEN1KMT2AGFER | |
| SCHEMBL10091696 | 0.90 | PIM1 (0.82) | PIM1POLBMEN1KMT2AGFER | |
| SCHEMBL10091745 | 0.90 | PIM1 (0.82) | PIM1POLBMEN1KMT2AGFER | |
| SCHEMBL31434323 | 0.88 | PIM1 (0.78) | PIM1POLBMEN1KMT2AGFER | |
| SCHEMBL31434329 | 0.88 | PIM1 (0.78) | PIM1POLBMEN1KMT2AGFER | |
| SCHEMBL31434391 | 0.88 | PIM1 (0.78) | PIM1POLBMEN1KMT2AGFER | |
| SCHEMBL31434376 | 0.88 | PIM1 (0.78) | PIM1POLBMEN1KMT2AGFER | |
| SCHEMBL10091744 | 0.88 | PIM1 (0.78) | PIM1POLBMEN1KMT2AGFER | |
| SCHEMBL31434335 | 0.88 | PIM1 (0.78) | PIM1POLBMEN1KMT2AGFER |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120190669-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190669-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-20120190669-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. (US) | 2012-07-26 | — | — | US | disclosed |
| US-8124649-B2 | Oxindole compounds | CYLENE PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124649-B2 | Oxindole compounds | CYLENE PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124649-B2 | Oxindole compounds | CYLENE PHARMACEUTICALS, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| EP-2307421-A1 | OXINDOLE COMPOUNDS | Cylene Pharmaceuticals, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20100041635-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20100041635-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20100041635-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. | 2010-02-18 | — | — | US | disclosed |
| WO-2010002933-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
| WO-2010002933-A1 | OXINDOLE COMPOUNDS | CYLENE PHARMACEUTICALS, INC. (US) | 2010-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041635-A1 | OXINDOLE COMPOUNDS | FLT3, PIM1, PIM2 | PIM1 2/4885POLB 2906/4885MEN1 3039/4885 |
| US-20120190669-A1 | OXINDOLE COMPOUNDS | FLT3, PIM1, PIM2 | PIM1 2/4885POLB 2906/4885MEN1 3039/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.